Investigation of the Effects of Dimethyl Sulfoxide in Experimental Gout with Comparison of Dexamethasone and Indomethacin

Basit Öğe Kaydı
dc.contributor.authorAydeger, Cemre
dc.contributor.authorAdali, Yasemen
dc.contributor.authorMakav, Mustafa
dc.contributor.authorEroglu, Hueseyin Avni
dc.date.accessioned2025-01-27T20:14:32Z
dc.date.available2025-01-27T20:14:32Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractGout arthritis is an inflammatory arthritis characterized by increased serum uric acid and accumulation of monosodium urate (MSU) crystals in soft tissues. The treatment for gout arthritis is centered on reducing uric acid agents with long-term and anti-inflammatory agents during attack times. In recent studies, it is noteworthy that Indomethacin and Dexamethasone have positive effects in the treatment of gout. Dimethyl sulfoxide (DMSO) is a lipophilic solvent and has an anti-inflammatory effect at appropriate doses. Based on this information, for this study, the effects of these three agents were investigated in rats using a gut model to compare their efficacy. In the study, a total of 48 female 3-4-month rats were divided equally into 8 groups: Control, Indomethacin, DMSO, Dexamethasone, Gout, Gout+Indomethacin, Gout+DMSO, Gout +Dexamethasone. During the eight-week study, a gout arthritis model was used that included 10 mg MSU given intra-articularly in the right foot. Indomethacin 12.5 mg/kg intragastric, DMSO 0.1 ml intraperitoneally and dexamethasone 0.2 mg/kg were administered subcutaneously to the related groups once a day for seven days. At the end of the study, collected articular tissues were stained with haematoxylin and eosin after the fixation and decalcification processes were done. The findings obtained showed that inflammation was reduced in treatment groups compared to the Control groups (all p values 0.002). Also, synovial proliferation was remarkably decreased in the Gout+Dexamethasone group compared to the Gout group (p = 0.019). As a result of these findings, although the three agents all reduced inflammation in gout arthritis, DMSO was shown to be more advantageous due to its having fewer side-effects.
dc.identifier.doi10.1007/s11094-024-03154-6
dc.identifier.endpage378
dc.identifier.issn0091-150X
dc.identifier.issn1573-9031
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85200510855
dc.identifier.scopusqualityQ4
dc.identifier.startpage373
dc.identifier.urihttps://doi.org/10.1007/s11094-024-03154-6
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21124
dc.identifier.volume58
dc.identifier.wosWOS:001272230200002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofPharmaceutical Chemistry Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectgout
dc.subjectmonosodium urate
dc.subjectindomethacin
dc.subjectDMSO
dc.subjectdexamethasone
dc.titleInvestigation of the Effects of Dimethyl Sulfoxide in Experimental Gout with Comparison of Dexamethasone and Indomethacin
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu